On Thursday, MaxLinear, Inc. (NYSE:MXL)’s shares inclined 5.99% to $12.73.
MaxLinear, Inc. (MXL), a provider of integrated, radio-frequency (RF) and mixed-signal integrated circuits for broadband communications, Pay-TV and the connected home, and data center, metro, and long-haul transport network applications, recently revised its financial outlook for the third quarter 2015.
MaxLinear presently anticipates revenue for the quarter ending September 30, 2015 to be about $95 million, contrast to preceding guidance of between $90 million and $94 million. MaxLinear also declared that it anticipates GAAP and non-GAAP gross margin for the third quarter 2015 to be about 53 percent and 57 percent, respectively, comprising with preceding guidance. GAAP and non-GAAP operating expenses are predictable to be about $49 million and $31 million, respectively, contrast to preceding guidance of about $50 million and $32 million, respectively.
MaxLinear, Inc. provides integrated, radio-frequency (RF) and mixed-signal circuits for broadband communication and data center, metro, and long-haul transport network applications worldwide.
Biogen Inc (NASDAQ:BIIB)’s shares gained 1.80% to $325.30.
PureTech Health plc, a science-driven healthcare company seeking to develop disruptive solutions to address unmet medical needs and improve the lives of patients, recently declared that Michael MacLean has been designated to PureTech’s administration team as Chief Financial Officer and Executive Vice President.
Michael MacLean joins PureTech from Iron Mountain Inc. (IRM), the FORTUNE 1000 global storage and information administration company, where he was Chief Financial Officer of its North American business overseeing $2.2bn of annual revenue and about $1bn of EBITDA. Formerly, Mr. MacLean was Senior Vice President, Finance and Chief Accounting Officer at Biogen (BIIB), a global biopharmaceutical company with annual revenues of more than $9bn, during which time he managed many of the finance and accounting functions and was responsible for structuring and managing collaborations and planned acquisitions. He also was an audit partner at global public accounting firms counting KPMG, one of the largest professional services companies in the world where he supported global clients in industries counting pharmaceuticals, medical devices and diagnostics.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients.
At the end of Thursday’s trade, VAALCO Energy, Inc. (NYSE:EGY)‘s shares surged 15.61% to $2.00.
VAALCO Energy, Inc. (EGY) declared that the North Tchibala 1-H well, the first development well drilled by VAALCO in the North Tchibala field, was brought online at a rate slightly in excess of 3,000 gross barrels of oil per day (about 750 barrels per day net revenue interest to VAALCO). The well was drilled to a measured depth of about 11,160 feet, targeting the undeveloped Dentale reservoir. The Dentale formation is productive in fields onshore Gabon, but this well represents the first Dentale production for the industry from that horizon in the offshore waters of Gabon.
The North Tchibala 1-H well was initially brought on production utilizing an electrical submersible pump (ESP), but was subsequently allowed to produce naturally. The well is not producing any formation water or hydrogen sulfide (H2S) and has a strong flowing tubing pressure in excess of 1,000 PSI. VAALCO plans to continue to produce the well without artificial lift while monitoring surface and downhole pressures.
VAALCO Energy, Inc., an independent energy company, acquires, explores for, develops, and produces crude oil and natural gas in the United States. The company owns producing properties and conducts exploration activities as an operator of consortiums internationally in Gabon and Angola, in addition to conducts exploration activities as a non-operator in Equatorial Guinea, West Africa.
ImmunoGen, Inc. (NASDAQ:IMGN), ended its Thursday’s trading session with 13.53% gain, and closed at $16.36.
ImmunoGen, Inc. ( IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, declared that investors, journalists and the general public are invited to listen to a live webcast of the Company’s analyst and investor event on September 18, 2015.
The event will focus on ImmunoGen’s strong foundation for growth, counting the advancement of its multi-product pipeline, its proprietary technology that is enabling the development of novel anticancer therapies and the Company’s core competencies that position it for success.
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugates technology. It offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
